(0.30%) 5 115.21 points
(0.25%) 38 334 points
(0.34%) 15 981 points
(-0.94%) $83.06
(5.51%) $2.03
(0.29%) $2 353.90
(0.68%) $27.72
(3.95%) $958.50
(-0.24%) $0.932
(-0.35%) $10.99
(-0.58%) $0.796
(1.67%) $93.41
Live Chart Being Loaded With Signals
QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories...
Stats | |
---|---|
本日の出来高 | 753 805 |
平均出来高 | 661 659 |
時価総額 | 8.67B |
EPS | €0.500 ( 2023-10-30 ) |
Last Dividend | €1.080 ( 2017-01-25 ) |
Next Dividend | €0 ( N/A ) |
P/E | 27.57 |
ATR14 | €0.0170 (0.04%) |
ボリューム 相関
Qiagen NV 相関
10 最も正の相関 |
---|
10 最も負の相関 |
---|
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Qiagen NV 相関 - 通貨/商品
Qiagen NV 財務諸表
Annual | 2023 |
収益: | €1.97B |
総利益: | €1.23B (62.77 %) |
EPS: | €1.540 |
FY | 2023 |
収益: | €1.97B |
総利益: | €1.23B (62.77 %) |
EPS: | €1.540 |
FY | 2022 |
収益: | €2.14B |
総利益: | €1.38B (64.65 %) |
EPS: | €1.860 |
FY | 2021 |
収益: | €2.25B |
総利益: | €1.45B (64.43 %) |
EPS: | €2.26 |
Financial Reports:
No articles found.
Qiagen NV Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
First Dividend | €1.080 | 2017-01-25 |
Last Dividend | €1.080 | 2017-01-25 |
Next Dividend | €0 | N/A |
Payout Date | 2017-01-31 | |
Next Payout Date | N/A | |
# dividends | 1 | -- |
Total Paid Out | €1.080 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 2.13 | -- |
Div. Sustainability Score | 10.00 | |
Div.Growth Potential Score | 3.99 | |
Div. Directional Score | 7.07 | -- |
Year | Amount | Yield |
---|
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
LAR.DE | Ex Dividend Knight | 2023-09-12 | Quarterly | 0 | 0.00% | |
UNP.DE | Ex Dividend Knight | 2023-08-30 | Quarterly | 0 | 0.00% | |
EBO.DE | Ex Dividend Junior | 2023-05-16 | Annually | 0 | 0.00% | |
NMM.DE | Ex Dividend Knight | 2023-09-06 | Quarterly | 0 | 0.00% | |
ADE.DE | Ex Dividend Junior | 2023-08-14 | Annually | 0 | 0.00% | |
ZEG.DE | Ex Dividend Knight | 2023-08-10 | Semi-Annually | 0 | 0.00% | |
GDX.DE | Ex Dividend Knight | 2023-10-05 | Quarterly | 0 | 0.00% | |
PPX.DE | Ex Dividend Knight | 2023-05-02 | Semi-Annually | 0 | 0.00% | |
BC8.DE | Ex Dividend Knight | 2023-05-26 | Annually | 0 | 0.00% | |
I93.F | Ex Dividend Junior | 2023-08-28 | Quarterly | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.174 | 1.500 | 6.53 | 9.79 | [0 - 0.5] |
returnOnAssetsTTM | 0.0558 | 1.200 | 8.14 | 9.77 | [0 - 0.3] |
returnOnEquityTTM | 0.0930 | 1.500 | -0.0782 | -0.117 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 1.990 | 0.800 | 5.05 | 4.04 | [1 - 3] |
quickRatioTTM | 1.458 | 0.800 | 6.13 | 4.90 | [0.8 - 2.5] |
cashRatioTTM | 0.619 | 1.500 | 7.67 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.251 | -1.500 | 5.82 | -8.74 | [0 - 0.6] |
interestCoverageTTM | 8.28 | 1.000 | 8.04 | 8.04 | [3 - 30] |
operatingCashFlowPerShareTTM | 2.08 | 2.00 | 9.31 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 1.340 | 2.00 | 9.33 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.402 | -1.500 | 8.39 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.628 | 1.000 | 2.87 | 2.87 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.225 | 1.000 | 7.50 | 7.50 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0.300 | 1.000 | 9.45 | 9.45 | [0.2 - 2] |
assetTurnoverTTM | 0.321 | 0.800 | -1.191 | -0.953 | [0.5 - 2] |
Total Score | 10.15 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 26.97 | 1.000 | 7.38 | 0 | [1 - 100] |
returnOnEquityTTM | 0.0930 | 2.50 | -0.0503 | -0.117 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 1.340 | 2.00 | 9.55 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 6.25 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 2.08 | 2.00 | 9.31 | 10.00 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | 0.0955 | 1.500 | -2.70 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.234 | 1.000 | 6.66 | 0 | [0.1 - 0.5] |
Total Score | 3.99 |
Qiagen NV
QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories. It also provides interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; assays for prenatal testing and detection of sexually transmitted diseases and HPV, as well as assays for analysis of genomic variants, such as mutations, insertions, deletions, and fusions; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. In addition, it offers PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping, and gene regulation instruments and technologies; human ID and forensics assay consumables, including STR assays for human ID, and assays for food contamination; PCR instruments consist of digital PCR solutions; and developed and configured OEM consumables. Further, the company provides predefined and custom NGS gene panels, library prep kits and components, and whole genome amplification; QIAGEN consumables and instruments, as well as bioinformatics solutions; and custom laboratory and genomic services. It serves molecular diagnostics, academia, pharmaceutical, and applied testing customers. It has a strategic alliance agreement with Sysmex Corporation and OncXerna Therapeutics, as well as an agreement with Mirati. The company was founded in 1986 and is headquartered in Venlo, the Netherlands.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。